These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 16106524

  • 1. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
    Kim KR, Rhee SD, Kim HY, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG.
    Eur J Pharmacol; 2005 Jul 25; 518(1):63-70. PubMed ID: 16106524
    [Abstract] [Full Text] [Related]

  • 2. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
    O'Harte FP, Mooney MH, Kelly CM, McKillop AM, Flatt PR.
    Regul Pept; 2001 Jan 12; 96(3):95-104. PubMed ID: 11111014
    [Abstract] [Full Text] [Related]

  • 3. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA.
    Eur J Pharmacol; 2011 Feb 10; 652(1-3):157-63. PubMed ID: 20540938
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR.
    Eur J Pharmacol; 2006 Oct 10; 547(1-3):192-9. PubMed ID: 16945366
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
    Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 May 10; 377(3):209-17. PubMed ID: 18398600
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, Saeki T, Tanaka I.
    J Pharmacol Exp Ther; 2006 Dec 10; 319(3):1253-7. PubMed ID: 16980568
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A, Yamamoto K, Kozakai A, Okumura-Kitajima L, Mita Y, Kitano K, Jingu S, Nakaike S.
    Eur J Pharmacol; 2011 Mar 25; 655(1-3):99-107. PubMed ID: 21262219
    [Abstract] [Full Text] [Related]

  • 13. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FP, Flatt PR.
    Eur J Pharmacol; 2007 Jul 30; 568(1-3):278-86. PubMed ID: 17573070
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
    Lee EY, Kim YW, Oh H, Choi CS, Ahn JH, Lee BW, Kang ES, Cha BS, Lee HC.
    Metabolism; 2014 Jun 30; 63(6):793-9. PubMed ID: 24684824
    [Abstract] [Full Text] [Related]

  • 16. Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model.
    Davis JA, Kumar PS, Singh S, Surender A, Roy S, Khanna V, Sethi S, Pal C, Sharma L, Benjamin B, Mittra S, Sattigeri J, Bansal VS.
    Indian J Pharmacol; 2012 Jun 30; 44(6):759-64. PubMed ID: 23248408
    [Abstract] [Full Text] [Related]

  • 17. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
    Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jetté L, Benquet C, Drucker DJ.
    Diabetes; 2003 Mar 30; 52(3):751-9. PubMed ID: 12606517
    [Abstract] [Full Text] [Related]

  • 18. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
    Mest HJ, Mentlein R.
    Diabetologia; 2005 Apr 30; 48(4):616-20. PubMed ID: 15770466
    [Abstract] [Full Text] [Related]

  • 19. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.
    Ahrén B, Holst JJ, Mårtensson H, Balkan B.
    Eur J Pharmacol; 2000 Sep 15; 404(1-2):239-45. PubMed ID: 10980284
    [Abstract] [Full Text] [Related]

  • 20. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O'Harte FP, Flatt PR.
    Biol Chem; 2004 Feb 15; 385(2):169-77. PubMed ID: 15101559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.